Clinical Nuclear Medicine最新文献

{"title":"Gastrin-Releasing Peptide Receptor Targeting PET/CT With 68 Ga-NOTA-RM26 in the Assessment of Glioma and Combined Multiregional Biopsies.","authors":"Rongxi Wang, Yilin Li, Ziyang Li, Jiarou Wang, Linlin Li, Jialin Xiang, Chenhao Jia, Xingtong Peng, Yu Wang, Wenbin Ma, Li'ao Wang, Wang Jia, Xiaoyuan Chen, Deling Li, Zhaohui Zhu, Jingjing Zhang","doi":"10.1097/RLU.0000000000005651","DOIUrl":"10.1097/RLU.0000000000005651","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of this study was to investigate the value of 68 Ga-NOTA-RM26 ( 68 Ga-RM26), a gastrin-releasing peptide receptor-targeting antagonist labeled with the radionuclide 68 Ga, in the diagnosis of high-grade gliomas and in combination with multiregional biopsies using PET/CT.</p><p><strong>Patients and methods: </strong>After institutional review board approval and informed consent, a total of 35 patients with suspected glioma lesions were enrolled in this study. All patients underwent 68 Ga-RM26 PET/CT scans within 2 weeks before surgery.</p><p><strong>Results: </strong>There were 8 grade II gliomas, 6 grade III gliomas, and 18 grade IV gliomas in a total of 32 glioma lesions. 68 Ga-RM26 PET/CT diagnosed 74.4% of lesions (27/32) of all glioma tumor types, and almost all high-grade gliomas were successfully diagnosed (23/24, 95.8%). Among the 9 negative glioma lesions, there were 8 low-grade gliomas (grade II). There was a significantly higher SUV max , SUV mean , and the lesion-to-background ratio (T/B ratio) in high-grade gliomas compared with low-grade gliomas ( P < 0.001). In addition, there was a high correlation between the immunohistochemical staining score of gliomas and parameters (SUV max , SUV mean , and T/B ratio) on 68 Ga-RM26 PET/CT ( P < 0.001), and verified by immunohistochemical staining on multiple-point samples of glioma lesions guided by 68 Ga-RM26 PET/CT.</p><p><strong>Conclusions: </strong>68 Ga-RM26 could noninvasively diagnose high-grade gliomas and be a promising PET tracer for predicting glioma grading before surgery. This pilot study indicated that the uptake of 68 Ga-RM26 correlates with WHO grade in glioma, and preoperative 68 Ga-RM26 PET/CT may be helpful to guide multiple-point biopsy of gliomas.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"316-323"},"PeriodicalIF":9.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142977902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"68 Ga-Pentixafor PET in Combination With MRI Improves the Differential Diagnosis of Glioblastoma and Primary Central Nervous System Lymphoma.","authors":"Zhenying Chen, Huimin Liu, Apeng Yang, Jingwei Liao, Zanyi Wu, Junmin Chen, Weibing Miao","doi":"10.1097/RLU.0000000000005657","DOIUrl":"10.1097/RLU.0000000000005657","url":null,"abstract":"<p><strong>Purposes: </strong>This study aims to investigate the diagnostic performance of combining 68 Ga-pentixafor PET with MRI to differentiate primary central nervous system lymphoma (PCNSL) from glioblastoma (GBM), particularly focusing on atypical lymphoma identification.</p><p><strong>Patients and methods: </strong>Seventy-one PCNSL and 53 GBM patients who underwent both 68 Ga-pentixafor PET/CT and MRI were retrospectively included. We evaluated the quantitative imaging parameters and MRI features of positive lesions, identifying atypical PCNSL by hemorrhage, necrosis, or heterogeneous enhancement. Logistic regression identified key variables, and the ROC-AUC evaluated their diagnostic value. Immunohistochemistry for CXCR4 was performed.</p><p><strong>Results: </strong>PCNSLs, including 23 atypical cases, showed higher SUV max and TBR, and lower MTV, ADC min , and relative ADC min (rADC min ) than GBMs (all P 's < 0.05). The CXCR4 staining in PCNSL was also more pronounced in GBM ( P = 0.048). Multivariate logistic regression indicated that a combination of TBR, MTV, and ADC min (quantitative model 1) had a superior AUC of 0.913 in distinguishing PCNSL from GBM, outperforming single parameters (all P 's < 0.05). For differentiating atypical PCNSL from GBM, single quantitatively parameters showed moderate performance (AUC, 0.655-0.767). Further combining TBR with ADC min (quantitative model 2) significantly improve the AUC to 0.883. Multiparameter models, incorporating significant quantitative and qualitative MRI features, achieved AUCs of 0.953 (PCNSL vs GBM) and 0.902 (atypical PCNSL vs GBM), significantly outperforming single parameters (all P 's < 0.05).</p><p><strong>Conclusions: </strong>68 Ga-pentixafor PET in combination with MRI provides valuable diagnostic information in differentiating PCNSL from GBM, especially for atypical PCNSL.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":"50 4","pages":"324-331"},"PeriodicalIF":9.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143536685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Value of 18 F-FDG PET in Primary Central Nervous System Lymphoma : Assessing Interim Metabolic Response for Improving Patient Stratification.","authors":"Ga-Young Song, Ho Cheol Jang, Mihee Kim, Seo-Yeon Ahn, Sung-Hoon Jung, Jae-Sook Ahn, Je-Jung Lee, Hyeoung-Joon Kim, Jang Bae Moon, Su Woong Yoo, Seong-Young Kwon, Jung-Joon Min, Hee-Seung Bom, Sae-Ryung Kang, Deok-Hwan Yang","doi":"10.1097/RLU.0000000000005703","DOIUrl":"10.1097/RLU.0000000000005703","url":null,"abstract":"<p><strong>Purpose of the report: </strong>The usefulness of brain 18 F-FDG PET/CT in primary central nervous system lymphoma (PCNSL) remains underexplored. This study investigated whether early metabolic responses in interim brain FDG PET/CT serve as a prognostic indicator of PCNSL treatment outcomes.</p><p><strong>Patients and methods: </strong>This prospective study included 53 patients with PCNSL who underwent a high-dose methotrexate-based treatment. Brain FDG PET was performed at diagnosis (baseline PET) and after induction chemotherapy (interim PET), assessing interim PET parameters such as the highest maximum standardized uptake value (hSUV max ), sum of SUV max (sumSUV max ), highest tumor-to-normal ratio (hTNR max ), sum of TNR max (sumTNR max ), highest metabolic tumor volume (MTV) (hMTV), and sum of MTV (sumMTV) across all PET-positive lesions.</p><p><strong>Results: </strong>High interim hTNR max (hazards ratio: 9.76, 95% confidence interval: 1.90-50.11, P = 0.01) was an independently significant predictor of poor progression-free survival in multivariate analysis. Patients with low interim hTNR max (≤1.0) had a significantly longer median progression-free survival than those with high interim hTNR max (>1.0) (25.0 vs 3.6 months, P < 0.001). Incorporating interim MRI-based clinical response assessments and hTNR max allowed the classification of partial response subgroups with markedly different prognoses ( P < 0.001). High interim hTNR max (hazards ratio: 2.76, 95% confidence interval: 1.39-5.48, P = 0.004) was an independently significant predictor of poor overall survival in multivariate analysis.</p><p><strong>Conclusions: </strong>The hTNR max measurement from interim brain FDG PET scans emerges as an important prognostic marker in PCNSL. These findings underscore the potential of interim FDG PET evaluations to refine response assessments and inform tailored therapeutic strategies.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"281-288"},"PeriodicalIF":9.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11878592/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143432477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"18 F-FAZA, 18 F-FDG, and 123 I-IMP Imaging Reveal Hypoxia and Metabolism in Acute MOGAD.","authors":"Kota Yokoyama, Junichi Tsuchiya, Hiroya Kuwahara, Motoki Inaji, Ukihide Tateishi","doi":"10.1097/RLU.0000000000005671","DOIUrl":"10.1097/RLU.0000000000005671","url":null,"abstract":"<p><strong>Abstract: </strong>We report the first case of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) evaluated with hypoxic imaging using 18 F-FAZA PET/CT. A healthy woman in her 20s presented to our hospital with seizures, headaches, and vomiting. MRI and CT scans suggested a wide range of differential diagnoses, from neoplastic lesions, such as malignant lymphoma, to inflammatory diseases, such as vasculitis, making her case challenging to diagnose. MOGAD was confirmed by positive myelin oligodendrocyte glycoprotein antibodies, and her condition improved with steroid therapy. The 18 F-FAZA PET/CT findings in this case may aid in understanding the pathogenesis of MOGAD.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"e236-e237"},"PeriodicalIF":9.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11878587/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pyomyositis Due to a Rare Fungal Infection-Findings on 68 Ga-NOTA UBI PET/CT.","authors":"Shubha Gadde Ravindra, Nishikant Avinash Damle, Pyata Vikram Babu, Danveer Bhadu, Gagandeep Singh","doi":"10.1097/RLU.0000000000005621","DOIUrl":"10.1097/RLU.0000000000005621","url":null,"abstract":"<p><strong>Abstract: </strong>It is very rare to see fungal arthritis and pyomyositis in immunocompetent patients. Here, we report a case of Scedosporium infection in an immunocompetent patient with interesting 18 F-FDG PET/CT and 68 Ga-NOTA UBI PET/CT findings.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"e207-e208"},"PeriodicalIF":9.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Translation of a Dual-Integrin αvβ3- and CD13-Targeting PET Tracer.","authors":"Xiao Zhang, Biao Yang, Chunxia Qin, Xiangming Song, Xiaoying Lv, Dexing Zeng, Yongkang Gai, Xiaoli Lan","doi":"10.1097/RLU.0000000000005647","DOIUrl":"10.1097/RLU.0000000000005647","url":null,"abstract":"<p><strong>Purpose: </strong>Angiogenesis is essential in the development and progression of tumors. This study aimed to investigate the clinical application of 68 Ga-labeled heterodimeric peptide ( 68 Ga-HX01) targeting integrin αvβ3 and CD13 in tumor neovascularization.</p><p><strong>Patients and methods: </strong>Six healthy volunteers were recruited to study the biodistribution, pharmacokinetics, and radiation of 68 Ga-HX01. Twelve patients with various malignancies were enrolled to seek the preliminary clinical value of 68 Ga-HX01. In healthy volunteers, SUVs of each major organ on 68 Ga-HX01 PET were measured. The clinical data, lesion numbers, and uptake were recorded in patients. The integrin αvβ3 and CD13 expression of the resected tumors was checked via immunohistochemistry staining.</p><p><strong>Results: </strong>With a mean injected dose of 167.98 ± 26.32 MBq, 68 Ga-HX01 was well tolerated and safe without side effects in 6 healthy volunteers. The radiation absorbed effective dose of 68 Ga-HX01 was 1.94 × 10 -2 mSv/MBq, and the urinary bladder wall held the highest absorbed effective dose (0.15 ± 5.87 × 10 -2 mSv/MBq). In 12 patients with various malignancies, 68 Ga-HX01 PET could clearly visualize the lesions from the surrounding tissues. The SUV max values in tumors were significantly higher than those in the surrounding tissues ( P < 0.05). A positive correlation trend between tumor SUV max and semiquantitative integrin αvβ3 and CD13 expression was determined ( P < 0.05).</p><p><strong>Conclusions: </strong>For clinical use, 68 Ga-HX01 is safe with low radiation absorbed effective dose. It also indicates the efficiency of dual integrin αvβ3 and CD13-targeting PET radiotracer in tumor diagnosis, which may assist in patient prognosis and selecting eligible patients for antiangiogenic therapy.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"332-337"},"PeriodicalIF":9.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143028022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of [ 68 Ga]FAPI PET/CT in Diagnosing Thymoma and Its Implications.","authors":"Paul Martin Dahlke, Carolin Senger, Jens-Carsten Rückert, Jens Neudecker, Christian Furth","doi":"10.1097/RLU.0000000000005650","DOIUrl":"10.1097/RLU.0000000000005650","url":null,"abstract":"<p><strong>Abstract: </strong>We report the case of a 71-year-old woman with recurrence of type B3 thymoma in which the diagnostic accuracy has benefited considerably from the additional use of [ 68 Ga]FAPI PET/CT when compared with the standard [ 18 F]FDG PET. [ 68 Ga]FAPI PET/CT confirmed the known lesions with higher lesion-to-background ratio and additionally identified a previously undetected lesion near the FDG-avid apex of the heart. This case demonstrates a potential superiority of [ 68 Ga]FAPI PET/CT in patients suffering from thymoma as detection of local recurrence close to metabolically active organs (ie, liver, heart) is improved. An improved planning of subsequent treatments (ie, lesion delineation for radiotherapy) appears possible.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"338-340"},"PeriodicalIF":9.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biodistribution and Dosimetry Evaluation of the Radiolabeled Somatostatin Receptor Antagonist 68 Ga-DATA 5m LM4 in Molecular Imaging of Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors Patients.","authors":"Sanjana Ballal, Parvind Sheokand, Madhav P Yadav, Frank Roesch, Rahul Viswanathan, Swayamjeet Satapathy, Madhavi Tripathi, Euy Sung Moon, Prashant Mishra, Sameer Rastogi, Shipra Agarwal, Chandrasekhar Bal","doi":"10.1097/RLU.0000000000005649","DOIUrl":"10.1097/RLU.0000000000005649","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to assess the biodistribution and radiation dosimetry of 68 Ga-DATA 5m LM4 in patients with gastroenteropancreatic neuroendocrine tumors.</p><p><strong>Patients and methods: </strong>Eight patients (5 females and 3 males) with various gastroenteropancreatic neuroendocrine tumors were included in the study. Each patient underwent 3 whole-body PET scans at 10, 60, and 120 minutes after receiving an IV injection of approximately 162.5 MBq of 68 Ga-DATA 5m LM4. Organs considered for dosimetric analysis included the liver, heart, spleen, kidneys, adrenal glands, and lumbar vertebrae (L2 to L4). Dosimetric calculations were performed using the OLINDA/EXM 2.2 software.</p><p><strong>Results: </strong>Physiological uptake of 68 Ga-DATA 5m LM4 was observed in the pituitary gland, spleen, liver, adrenal glands, and the urinary tract (kidneys and urinary bladder) for all patients. The kidneys received the highest absorbed doses at (4.77E-02 ± 1.49E-02 mSv/MBq). The mean effective dose was 2.61E-03 ± 5.99E-04 mSv/MBq.</p><p><strong>Conclusions: </strong>68 Ga-DATA 5m LM4 injection is safe and is primarily excreted through urine, delivering the highest radiation dose to the kidneys.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":"50 4","pages":"e194-e201"},"PeriodicalIF":9.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143536688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Malignant Phyllodes Tumor With Sphenoid Bone Metastasis Detected on 99m Tc-MDP SPECT/CT and 18 F-FDG PET/CT.","authors":"Ritwik Wakankar, Yamini Dharmashaktu, Akhil Venugopal, Rakesh Kumar","doi":"10.1097/RLU.0000000000005632","DOIUrl":"10.1097/RLU.0000000000005632","url":null,"abstract":"<p><strong>Abstract: </strong>Phyllodes tumors (PTs) are rare fibroepithelial tumors accounting for less than 1% of all breast neoplasms. They are malignant in 20% of cases. Only a few cases of malignant PT metastatic to bone have been reported. We report a case of metastatic malignant PT of the breast involving the greater wing of the sphenoid bone and discuss the radiological findings of 99m Tc-methylene diphosphonate skeletal scintigraphy, SPECT/CT, and 18 F-FDG PET/CT. To our knowledge, this is the first time such a case has been reported in literature.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"e223-e224"},"PeriodicalIF":9.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142784282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"18 F-DCFPyL in the Detection of Prostate Cancer Spread to the Lumbosacral Plexus.","authors":"Silmara R Segala, Duncan Sutherland, Glenn Bauman, Brandon Driscoll, Joseph Chin, Jonathan Romsa, Katherine A Zukotynski","doi":"10.1097/RLU.0000000000005472","DOIUrl":"10.1097/RLU.0000000000005472","url":null,"abstract":"<p><strong>Abstract: </strong>In most cases, prostate cancer spreads locally to the seminal vesicles, via lymphatics to pelvic and abdominal lymph nodes, and hematogenously to the bones. Direct invasion along nerve roots is exceptionally rare but can occur. Here, we present a case with 18 F-DCFPyL PET/CT images showing neoplastic involvement of the lumbosacral plexus in a patient with recurrent prostate cancer.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"e232-e233"},"PeriodicalIF":9.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}